Close Menu

The lack of clear guidance from the US Food and Drug Administration regarding KRAS testing to target treatment with anti-EGFR monoclonal antibodies for colorectal cancer is affecting sales of such drugs and putting drugmakers in a difficult spot with regard to what they can and cannot say to doctors.

During an earnings call Last week, BMS said confusion over KRAS testing caused fourth-quarter US sales of its colorectal cancer drug Erbitux to slide 2 percent to $179 million from the year-ago period.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

President Donald Trump announced the US would be leaving the World Health Organization, NBC News reports.

CDC head says a new analysis indicates earlier testing wouldn't have caught viral spread, NPR reports.

A study of Great Danes homes in on a genomic region linked to fearfulness.

In PLOS this week: gene expression and epigenetics of Indonesian populations, hookworm parasite secretome, and more.

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.